PCJ Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Early Commercial Revenue TractionRapid revenue pick-up from the ZEVASKYN launch demonstrates initial commercial product-market fit and establishes a real revenue base. Durable because it validates the commercial model, supports recurring treatment revenue via QTCs, and de-risks transition from pure R&D toward sustaining operations over coming quarters.
Solid Gross Margins (~52%)A ~52% gross margin provides structural room to absorb SG&A and R&D while moving toward profitability as volumes grow. With commercial patients driving favorable gross-to-net and manufacturing costs shifting from R&D to inventory, margins can sustain improved leverage as throughput and payor mix normalize.
Manageable Leverage And Larger Balance SheetLow debt relative to equity and a scaled balance sheet give financial flexibility to fund commercialization and near‑term clinical activities without immediate refinancing. This structural strength reduces bankruptcy risk and supports strategic options over the next several quarters.
Bears Say
Persistent Cash Burn And Negative Operating Cash FlowSustained negative operating and free cash flow indicate the business relies on external financing to continue operations. Despite early sales, heavy cash burn constrains runway, increases dilution risk, and limits ability to scale QTC network or fund trials without new capital over the medium term.
Earnings Quality DisconnectPositive net income driven by non‑operational or one‑time items while EBIT and EBITDA remain deeply negative reduces confidence in reported profitability. This structural disconnect complicates forecasting cash generation and undermines the reliability of earnings as a signal for sustainable performance.
Elevated SG&A And Scaling CostsHigh fixed selling and admin costs and rising cost of sales during launch mean the company must achieve steady QTC throughput to cover overhead. Prolonged ramp times, onboarding complexity and multi‑month variability in biopsies raise the break‑even hurdle and extend the period of negative operating leverage.
Abeona Therapeutics News
PCJ FAQ
What was Abeona Therapeutics Inc’s price range in the past 12 months?
Currently, no data Available
What is Abeona Therapeutics Inc’s market cap?
Currently, no data Available
When is Abeona Therapeutics Inc’s upcoming earnings report date?
Abeona Therapeutics Inc’s upcoming earnings report date is Aug 12, 2026 which is in 19 days.
How were Abeona Therapeutics Inc’s earnings last quarter?
Abeona Therapeutics Inc released its earnings results on May 13, 2026. The company reported -$0.245 earnings per share for the quarter, beating the consensus estimate of -$0.274 by $0.029.
Is Abeona Therapeutics Inc overvalued?
According to Wall Street analysts Abeona Therapeutics Inc’s price is currently Undervalued.
Does Abeona Therapeutics Inc pay dividends?
Abeona Therapeutics Inc does not currently pay dividends.
What is Abeona Therapeutics Inc’s EPS estimate?
Abeona Therapeutics Inc’s EPS estimate is -0.19.
How many shares outstanding does Abeona Therapeutics Inc have?
Currently, no data Available
What happened to Abeona Therapeutics Inc’s price movement after its last earnings report?
Abeona Therapeutics Inc reported an EPS of -$0.245 in its last earnings report, beating expectations of -$0.274. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Abeona Therapeutics Inc?
Currently, no hedge funds are holding shares in CH:PCJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abeona Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.13 (― Downside)
$16.13 (― Downside)
Insider Transactions
Sold Shares
Worth CHF1.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
99.76%
Trailing 12-Months
Company Description
Abeona Therapeutics Inc
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
PCJ Stock 12 Month Forecast
Average Price Target
$16.13